Latest news
AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 20:14:43 GMTThis Stock Keeps Raising Its Dividend No Matter What the Market Does -- and Wall Street Thinks It's a Buy Right Now - The Globe and MailThe Globe and Mail · Thu, 06 Aug 2026 01:29:03 GMTAbbVie Inc. Stock 12‑Month Price Target Raised to $275.44, Implies 13% Upside - TradingViewTradingView · Wed, 05 Aug 2026 21:20:22 GMTAbbVie (ABBV) Lifted Guidance, Has The Market Already Priced It In? - simplywall.stsimplywall.st · Tue, 04 Aug 2026 15:17:34 GMTGuggenheim raises Abbvie stock price target to $288 on strong Q2 - Investing.comInvesting.com · Tue, 04 Aug 2026 13:32:10 GMTAbbVie raises annual net revenue outlook by $300M to ~$67.6B - scanx.tradescanx.trade · Fri, 31 Jul 2026 17:28:46 GMTAbbVie's Skyrizi shrugs off new competition as it thrives in growing psoriasis market - Fierce PharmaFierce Pharma · Fri, 31 Jul 2026 15:18:04 GMTAbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now? - The Motley FoolThe Motley Fool · Wed, 29 Jul 2026 07:00:00 GMT